Suppression of adjuvant-induced disease (AID) by a novel analgesic-opioid agonist which also possesses antioxidant activity (neuroimmunomodulation).
A centrally acting analgesic-opioid agonist, PM, suppresses the primary inflammation and the secondary lesions of adjuvant-induced disease in rats. This compound also possesses antioxidant properties and inhibits the carrageenin-induced edema in mice. PM, therefore, is interfering to immune functions probably by binding to opioid receptors on lymphocytes and to inflammatory cells by its antioxidant activity.